Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Erica Evans, Justin F. Gainor et al.|Cancer Discovery|2018Cited by 392
Denosumab for Treatment of Hypercalcemia of MalignancyMimi I. Hu, Rajul K. Jain, Ilya Glezerman et al.|The Journal of Clinical Endocrinology & Metabolism|2014Cited by 200
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistanceSarah Hamidi, Ramona Dadu, Marie‐Claude Hofmann et al.|Frontiers in Endocrinology|2023Cited by 49
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancerVivek Subbiah, Jie Wu, Luz E. Castellanos et al.|npj Precision Oncology|2024Cited by 24
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancersMirella Nardo, Vivek Subbiah, Mohamed A. Gouda et al.|Cell Reports Medicine|2023Cited by 22